Amgen/Abgenix’ Panitumumab Slows Colorectal Cancer Progression By 46%
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Amgen's pivotal Phase III study of panitumumab for third-line metastatic colorectal cancer treatment showed a highly statistically significant 46% decrease in tumor progression rate compared to best supportive care (p<0.000000001)